The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience.

IF 1.9 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Breast Journal Pub Date : 2023-01-01 DOI:10.1155/2023/4549033

Ismail Can Tercan, Baha Zengel, Ozlem Ozdemir, Demet Cavdar, Funda Tasli, Zehra Hilal Adibelli, Murat Karatas, Cenk Simsek, Isabel Raika Durusoy, Adam Uslu

{"title":"The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience.","authors":"Ismail Can Tercan, Baha Zengel, Ozlem Ozdemir, Demet Cavdar, Funda Tasli, Zehra Hilal Adibelli, Murat Karatas, Cenk Simsek, Isabel Raika Durusoy, Adam Uslu","doi":"10.1155/2023/4549033","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC).Methods: Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or ≤ 1 mm residual tumor in the breast and/or presence of malignant cell clusters (≤0.2 mm) and/or micrometastases (≤2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi).Results: The mean age of the 92 patients was 49.6 ± 10.3 years and the mean follow-up was 34.0 ± 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months (p=0.063).Conclusions: In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR.","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 ","pages":"4549033"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833895/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/4549033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC).

Methods: Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or ≤ 1 mm residual tumor in the breast and/or presence of malignant cell clusters (≤0.2 mm) and/or micrometastases (≤2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi).

Results: The mean age of the 92 patients was 49.6 ± 10.3 years and the mean follow-up was 34.0 ± 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months (p=0.063).

Conclusions: In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR.

Abstract Image

查看原文本刊更多论文

对新辅助化疗完全缓解的淋巴结阳性乳腺癌患者前哨淋巴结活检的肿瘤学安全性:单中心研究。

目的:评价乳腺癌新辅助化疗(NAC)完全缓解患者前哨淋巴结活检(SLNB)的有效性和安全性。方法:连续92例(T1-4和N1-2)有病理和/或临床和放射学腋窝淋巴结受累的乳腺癌患者。所有患者均接受NAC治疗。NAC术后腋窝临床和放射学完全缓解的患者行SLNB。病理完全缓解(ypCR)被定义为没有残留的浸润性和原位癌，接近完全缓解(ypNCR)代表乳腺原位和/或≤1mm残留肿瘤和/或腋窝淋巴结(ALN) (ypTis/T1mi, ypN0i+/pN1mi)存在恶性细胞团(≤0.2 mm)和/或微转移(≤2.0 mm)。结果:92例患者平均年龄49.6±10.3岁，平均随访34.0±17.8个月。对于乳腺肿瘤，23例(25.0%)患者对NAC有完全缓解，14例(15.2%)患者对NAC有接近完全缓解。39例(42.4%)ALN患者完全缓解，6例(6.5%)患者接近完全缓解。平均随访34个月，33例实现ypCR和ypNCR的患者的总生存率为100%，其余59例对NAC部分或无反应的患者的总生存率为83.1% (p=0.063)。结论:在本研究中，ypCR和ypNCR在乳房和腋窝未发生任何事件。在长期随访中，相同结果的持续性可能使ypNCR作为除ypCR外的阳性预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Journal 医学-妇产科学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.